Muminah is a teenager living with vernal keratoconjunctivitis (VKC), a rare condition characterized by inflammation of the conjunctiva, the eye’s outer membrane. In this video, Muminah shares her ...

Terran Biosciences' founder and CEO Sam Clark talks about big opportunities for prodrug development in 2025, the importance of a strong medicinal chemistry team, and a potential increase in M&A ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

With the European Union's Medical Devices Regulation now in full effect, manufacturers face the imperative task of comprehending and adhering to its stipulations. Manufacturers must ascertain their ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

NCBiotech and their coalition of partners received a $25 million Phase 2 award from the U.S. Economic Development Administration’s Build Back Better Regional Challenge. This award will further ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski discuss their companies’ partnership, Life’s pipeline, and Columbus’ biotech hub.

Materials used in a drug package or device design are fundamental to ensuring a safe and effective drug development program. The recent growth in complex therapeutics has increased demand for ...

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and ...

The recombinant adeno-associated virus vector (rAAV), for example, the rAAV5 serotype, has been widely evaluated as a gene therapy delivery system. Here, we show how a HyClone™ peak expression cell ...

Oxygen is the second leading cause for quality degradation of pharmaceuticals, water being the first. While we typically think of packaging as the primary resource used to protect drugs from the ...